Al­ny­lam shares dip on a de­ci­sion to scrap ac­cel­er­at­ed pitch on givosir­an; Loxo gets a 'break­through' at the FDA

Al­ny­lam $AL­NY has de­cid­ed to put a hold on its plans to shoot for an ac­cel­er­at­ed ap­proval of givosir­an and in­stead start …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.